NeoGenomics Valuation
| NEO Stock | USD 9.13 0.03 0.33% |
At this time, the firm appears to be undervalued. NeoGenomics secures a last-minute Real Value of $10.8 per share. The latest price of the firm is $9.13. Our model forecasts the value of NeoGenomics from analyzing the firm fundamentals such as Profit Margin of (0.15) %, return on equity of -0.12, and Current Valuation of 1.49 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting NeoGenomics' valuation include:
Price Book 1.4804 | Enterprise Value | Enterprise Value Ebitda 945.3908 | Price Sales 1.6241 | Forward PE 222.2222 |
Undervalued
Today
Please note that NeoGenomics' price fluctuation is somewhat reliable at this time. Calculation of the real value of NeoGenomics is based on 3 months time horizon. Increasing NeoGenomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since NeoGenomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NeoGenomics Stock. However, NeoGenomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.13 | Real 10.8 | Target 14.81 | Hype 8.9 | Naive 9.24 |
The intrinsic value of NeoGenomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NeoGenomics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NeoGenomics helps investors to forecast how NeoGenomics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NeoGenomics more accurately as focusing exclusively on NeoGenomics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use NeoGenomics' intrinsic value based on its ongoing forecasts of NeoGenomics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against NeoGenomics' closest peers.
NeoGenomics Cash |
|
NeoGenomics Total Value Analysis
NeoGenomics is now forecasted to have company total value of 1.49 B with market capitalization of 1.18 B, debt of 472.28 M, and cash on hands of 465.95 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the NeoGenomics fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.49 B | 1.18 B | 472.28 M | 465.95 M |
NeoGenomics Investor Information
About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.48. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NeoGenomics has Price/Earnings To Growth (PEG) ratio of 2.09. The entity recorded a loss per share of 0.84. The firm had not issued any dividends in recent years. NeoGenomics had 1:100 split on the 16th of April 2003. Based on the key indicators related to NeoGenomics' liquidity, profitability, solvency, and operating efficiency, NeoGenomics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.NeoGenomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NeoGenomics has an asset utilization ratio of 53.49 percent. This suggests that the Company is making $0.53 for each dollar of assets. An increasing asset utilization means that NeoGenomics is more efficient with each dollar of assets it utilizes for everyday operations.NeoGenomics Profitability Analysis
Based on NeoGenomics' profitability indicators, NeoGenomics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in April. Profitability indicators assess NeoGenomics' ability to earn profits and add value for shareholders.Net Loss | First Reported 1999-03-31 | Previous Quarter -27.1 M | Current Value -9.9 M | Quarterly Volatility 13.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.26 | 0.3885 |
|
|
For NeoGenomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NeoGenomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NeoGenomics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NeoGenomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NeoGenomics over time as well as its relative position and ranking within its peers.
NeoGenomics Earnings per Share Projection vs Actual
The next projected EPS of NeoGenomics is estimated to be 0.035 with future projections ranging from a low of 0.02 to a high of 0.04. NeoGenomics' most recent 12-month trailing earnings per share (EPS TTM) is at -0.84. Please be aware that the consensus of earnings estimates for NeoGenomics is based on EPS before non-recurring items and includes expenses related to employee stock options.NeoGenomics Earnings Estimation Breakdown
The calculation of NeoGenomics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of NeoGenomics is estimated to be 0.035 with the future projection ranging from a low of 0.02 to a high of 0.04. Please be aware that this consensus of annual earnings estimates for NeoGenomics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.02 Lowest | Expected EPS | 0.04 Highest |
NeoGenomics Earnings Projection Consensus
Suppose the current estimates of NeoGenomics' value are higher than the current market price of the NeoGenomics stock. In this case, investors may conclude that NeoGenomics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and NeoGenomics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 13 | 20.0% | 0.0 | 0.035 | -0.84 |
NeoGenomics Ownership Allocation
NeoGenomics maintains a total of 129.81 Million outstanding shares. The majority of NeoGenomics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in NeoGenomics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in NeoGenomics. Please pay attention to any change in the institutional holdings of NeoGenomics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.NeoGenomics Profitability Analysis
The company reported the last year's revenue of 727.33 M. Reported Net Loss for the year was (108.03 M) with profit before taxes, overhead, and interest of 313.89 M.About NeoGenomics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of NeoGenomics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of NeoGenomics based exclusively on its fundamental and basic technical indicators. By analyzing NeoGenomics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of NeoGenomics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of NeoGenomics. We calculate exposure to NeoGenomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NeoGenomics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 282.5 M | 296.7 M | |
| Pretax Profit Margin | (0.15) | (0.16) | |
| Operating Profit Margin | (0.09) | (0.10) | |
| Net Loss | (0.15) | (0.16) | |
| Gross Profit Margin | 0.39 | 0.26 |
NeoGenomics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 25.6 M | |
| Quarterly Earnings Growth Y O Y | 1.306 | |
| Forward Price Earnings | 222.2222 |
NeoGenomics Current Valuation Indicators
NeoGenomics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final NeoGenomics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as NeoGenomics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use NeoGenomics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes NeoGenomics' worth.When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Will Health Care Providers & Services sector continue expanding? Could NeoGenomics diversify its offerings? Factors like these will boost the valuation of NeoGenomics. Anticipated expansion of NeoGenomics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NeoGenomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.306 | Earnings Share (0.84) | Revenue Per Share | Quarterly Revenue Growth 0.106 | Return On Assets |
Investors evaluate NeoGenomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NeoGenomics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause NeoGenomics' market price to deviate significantly from intrinsic value.
It's important to distinguish between NeoGenomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NeoGenomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NeoGenomics' market price signifies the transaction level at which participants voluntarily complete trades.